Literature DB >> 15239143

Allelic loss but absence of mutations in the polyspecific transporter gene BWR1A on 11p15.5 in hepatoblastoma.

Steffen Albrecht1, Wolfgang Hartmann, Farzad Houshdaran, Arend Koch, Barbara Gärtner, Dirk Prawitt, Bernhard U Zabel, Pierre Russo, Dietrich Von Schweinitz, Torsten Pietsch.   

Abstract

Chromosomal region 11p15.5 shows frequent maternal allelic loss in embryonal tumors, including rhabdomyosarcoma (RMS), Wilms' tumor (WT) and hepatoblastoma (HB), consistent with the presence of at least one tumor suppressor gene in this region, which should be paternally imprinted, i.e., expressed from the maternal allele only. The BWR1A gene encodes a polyspecific transmembrane transporter and is located on 11p15.5. It is highly expressed in liver, paternally imprinted and was found to be mutated in an RMS cell line, making it a plausible tumor suppressor gene for HB. We therefore screened 62 HBs, 3 HB cell lines and 1 pediatric hepatocellular carcinoma for BWR1A mutations using single-strand conformation polymorphism analysis. Allelic loss on 11p15.5 was assessed by PCR-based microsatellite analysis in 56 of the cases for which constitutional DNA was available. BWR1A mRNA expression was determined in 14 HBs by differential RT-PCR of matched cDNA samples from tumor and normal liver. Western blot analysis was performed on 4 tumors and matching normal liver tissue. Except for sequence polymorphisms (in exons 2, 3 and 10 as well as in introns 6 and 7), no mutations were found. Thirteen HBs (23%) had allelic loss on 11p15.5; this included BWR1A in 12 but it was telomeric to BWR1A in 1. Expression of BWR1A mRNA was reduced in 11 out of 14 cases by 19-92%, independent from allelic loss of 11p15.5. By Western blot analysis, all 4 tumors and matching liver samples displayed a 48-51 kd band corresponding to BWR1A. These results make it unlikely that BWR1A is the target of the allelic deletions in HB. However, similar to the putative 11p15.5 tumor suppressor H19, BWR1A appears to be reduced in expression. Reduced expression in the absence of mutations may contribute to HB development; however, to understand the significance of this finding will require further studies on the function of BWR1A, specifically its role in liver development. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239143     DOI: 10.1002/ijc.20280

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18.

Authors:  S-H Chu; Z-M Zhou; S Karri; Z-Q Li; J-M Zhao
Journal:  Cancer Gene Ther       Date:  2014-01-31       Impact factor: 5.987

2.  Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105.

Authors:  H Y Yamada; G J Gorbsky
Journal:  Oncogene       Date:  2006-03-02       Impact factor: 9.867

3.  Elevated expression of solute carrier family 22 member 18 increases the sensitivity of U251 glioma cells to BCNU.

Authors:  Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Hong Zhang; Jian-Hua Qiu; Zhi-An Zhu
Journal:  Oncol Lett       Date:  2011-08-04       Impact factor: 2.967

4.  Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma.

Authors:  Sheng-Hua Chu; Dong-Fu Feng; Yan-Bin Ma; Hong Zhang; Zhi-An Zhu; Zhi-Qiang Li; Pu-Cha Jiang
Journal:  J Transl Med       Date:  2011-09-21       Impact factor: 5.531

5.  Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.

Authors:  Yeonjoo Jung; Yukyung Jun; Hee-Young Lee; Suyeon Kim; Yeonhwa Jung; Juhee Keum; Yeo Song Lee; Yong Beom Cho; Sanghyuk Lee; Jaesang Kim
Journal:  Oncotarget       Date:  2015-09-22

6.  Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.

Authors:  Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Zhi-Qiang Li; Pu-Cha Jiang
Journal:  J Transl Med       Date:  2013-03-20       Impact factor: 5.531

7.  Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma.

Authors:  S Honda; Y Arai; M Haruta; F Sasaki; M Ohira; H Yamaoka; H Horie; A Nakagawara; E Hiyama; S Todo; Y Kaneko
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.